Tubulis raises €128.0M Series B round

The proceeds will primarily support progress in Tubulis' pipeline of next-generation ADCs toward clinical evaluation, help achieve clinical proof-of-concept for lead candidates TUB-040 and TUB-030, fund expansion of technology platforms, and establish a US subsidiary.

Source: https://www.tubulis.com/tubulis-closes-upsized-e128-million-series-b2-to-accelerate-clinical-development-of-solid-tumor-focused-adc-pipeline/